[e-drug] Save the Drug Therapeutics Bulletin!

E-DRUG: Save the Drug Therapeutics Bulletin!
-------------------------------------------

[This message is first of all for UK E-druggers, but I am sure others may participate to show that the journal is important alos outside the UK. If you need a generic letter, please respond to Merav directly as E-drug cannot post attachments. KM, moderator]

The Drugs and Therapeutics Bulletin (DTB) has been providing NHS doctors in
England with independent information about new medications for over 20
years. Up until now, the bulletin has been funded by the Department of
Health and Which?. However on 31 March 2006, the Department of Health failed
to renew the contract.

Over the years, DTB has initiated successful campaigns for the removal or
restriction of medicines that it could not recommend; prompted withdrawal of
inappropriate promotional claims, e.g. the withdrawal of UK advertising for
Yasmin, a combined oral contraception pill, and more recently, Viteyes, a
nutritional supplement for macular degeneration; and exposed fundamental
weaknesses in certain treatment policy and prescribing practice, e.g. in
articles on 'Are rofecoxib and celecoxib safer NSAIDS?'; 'mild depression in
general practice: time for rethink?'; and 'Simvastatin over the counter'.

The contract for national provision of DTB had been capped at £1.4 million
per year over a 6 year period. This is in the context of an NHS drug budget
of around £8 billion per year and a pharmaceutical industry annual spend on
promotion of £1.65 billion. DTB testimonials from a broad range of
healthcare professionals confirm that the central provision of DTB is of
enormous value to the NHS. In particular, clinicians see that DTB is crucial
to the NHS in providing a balance to the promotional activities of the
pharmaceutical industry. The fact that this view was echoed strongly by the
Government and Department of Health at the recent Health Select Committee
inquiry into the influence of the Pharmaceutical Industry shows the
hollowness of the Department of Health’s argument in terminating DTB’s
contract.

We are asking that you help to reverse this decision by the Department of
Health. To do this, we are joining DTB in a letter campaign. Write a letter
and send it to:

Rt Hon Patricia Hewitt MP
Secretary of State for Health
Department of Health
Richmond House
79 Whitehall
London SW1A 2NS

Alternatively, you can send an email to HYPERLINK
dhmail@doh.gsi.gov.uk.

In addition, please send the other letter to your local MP. You can find
his/her address and email at HYPERLINK
http://www.locata.co.uk/commons/.

We feel that a letter would be more effective as it is less easily ignored
however if you are short of time, an email would also be effective.

We have attached 2 generic letters which are ready to be sent out if you do
not have the time to write a personalised one.

Please take the time to help us to ensure the future of this important
resource.

Merav Kliner
PharmAware National Committee UK
HYPERLINK leeds@pharmaware.co.uk
HYPERLINK www.pharmaware.co.uk

E-DRUG: Save the Drug Therapeutics Bulletin! (2)
-------------------------------------------

Dear E-druggers,

I do sympathize with the DTB staff and with Ms
Hewitt, but one should just look at those
bulletins which survived without outside support,
simply on the basis of their high quality: First
of all Revue Prescrire, but also the Medical
Letter on Drugs and Therapeutics, Pharma-Kritik,
Arznei-Telegramm.... Make the outlook and the
contents attractive and challenging, and you will
find subscribers. Subsidies cannot save mediocre
bulletins - just look at the Dutch remnant. Even
a good (free) Internet journal could be an alternative.

Good luck,

Leo Offerhaus
he Netherlands
offerhausl@euronet.nl

E-DRUG: Save the Drug Therapeutics Bulletin! (3)
--------------------------------------------

Dear E-drug friends,

In this case I do not agree with Leo Offerhaus (althoughI usually do....). A 'free' high quality Drug Bulletin is an asset to the (medical) society.

Practitioners who take a subscription to an independent drug-bulletin are
usually already quite critical of medicines and medicine use. A freely
distributed drug-bulletin may also influence the practitioners who usually
would not pay much attention to their prescribing behaviour or to what they
prescribe!

The excellent and high quality bulletin 'La Revue Prescrire', also is a good example for this. Only 14.000 of the 28.000 subscribers are medical
specialists or generalists, and France counts around 200.000 practicing
doctors. So, the journal is only send to 7% of the prescribers (and those are the 'believers') in France and therefore its impact can only be limited.
I personally would prefere a high quality bulletin to be distributed to all
prescribers, and maybe pharmacists as well.

And btw, Prescrire has also had external support in the past!
[Yes until the French government stopped funding it, similar to what happens to DTB now. KM, moderator]

Foppe van Mil
Pharmacy Practice Consultant
Chairman of Pharma Selecta Foundation

E-DRUG: Save the Drug Therapeutics Bulletin! (4)
-------------------------------------------

The thousand dollar question remains: Does a "non-believer" who
receives free copies of a drug bulletin improve his/her prescribing
habits or does it not make any difference? I remember a newly
appointed professor of medicine who left all his unread copies of the
Lancet in his car boot for everyone to see - because he pretended
that he had no time to read all that stuff, and even not to open the
covers.... It all comes back to the main issue: The average medical
practitioner does not read and pretends to have no time. At times I
am quite pessimistic.

Best wishes,

Leo Offerhaus.
The Netherlands
offerhausl@euronet.nl

E-DRUG: Save the Drug Therapeutics Bulletin! (5)
-------------------------------------------

Dear E-druggers,

An electronic (internet-based) journal sounds very interesting: could this
be a collaborative project for ISDB members?

[ISDB is the International Society of Drug Bulletins]

Philippa.

Philippa Saunders
Essential Drugs Project
77 Lee Road
Blackheath
London SE3 9EN
UK

tel/fax 44 (0)20 8318 1419
email edp@gn.apc.org
-----------------------------------

E-DRUG: Save the Drug Therapeutics Bulletin! (6)
-------------------------------------------

Respected Members

I fully agree with Leo. In india medical journals are read only by medical
students and doctors working in teaching institutions.
Perhaps the time has come for medical journal publishers and editors to
start thinking -why doctors dont read medical journals and what they want to
read.
In 1993 i made survey of 300 GPs on this aspect. I found
60% of doctors in GP practice forget 50% of what they are taught in medical
school. They always prefered to read what they forgot rather than the latest
devlopment which they can not put in to practice. Of course this situation
in india continues same way.

regards

V.Bhava Narayana
Editor
Pharmed Trade News
3-3-62/A,New Gokhale Nagar,
Ramanthapur,Hyderabad-500 013.
Phone :91-40-27030681,32995727
Mob 919849551183,919323131524
Mobile:91-98495-51183
www.pharmedtradenews.com